Physician profile
Kristen Renee Spencer
NPI 1720400906
$50,168.93
in general payments reported to CMS, 2019-2025
29 companies · $21K in 2025
The $21K reported for 2025 was more than what 88% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $136 · 2021: $5,200 · 2022: $3,418 · 2023: $7,701 · 2024: $13K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $33K · Travel and Lodging: $4,276 · Food and Beverage: $2,147 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $32,931.50 |
| Travel and Lodging | $4,276.00 |
| Food and Beverage | $2,146.72 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $15,342.50 | 2023-2025 | Imfinzi, Airsupra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $10,229.43 | 2024 | Fruzaqla |
| Jazz Pharmaceuticals INC. | $9,202.22 | 2024-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $8,340.32 | 2021-2022 | |
| Genentech USA, INC. | $2,099.10 | 2019-2024 | Tecentriq |
| Exelixis INC. | $1,800.00 | 2023 | Cabometyx |
| Caris Mpi, INC. | $1,750.00 | 2025 | Mi Cancer Seek |
| Merck Sharp & Dohme LLC | $500.00 | 2024 | |
| Foundation Medicine, INC. | $229.00 | 2022 | |
| Beone Medicines USA, INC. | $164.04 | 2025 | Tevimbra |
| Array Biopharma INC | $138.67 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2023 | |
| Mirati Therapeutics, INC. | $108.94 | 2023 | Krazati |
| Ipsen Biopharmaceuticals, INC | $91.50 | 2025 | Onivyde |
| Glaxosmithkline, LLC. | $34.38 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $13.83 | 2022 |
13 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Spencer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.